Literature DB >> 19098711

RYBP stabilizes p53 by modulating MDM2.

Deng Chen1, Jianbing Zhang, Mao Li, Elizabeth R Rayburn, Hui Wang, Ruiwen Zhang.   

Abstract

The mouse double minute 2 (MDM2)-p53 interaction regulates the activity of p53 and is a potential target for human cancer therapy. Here, we report that RYBP (RING1- and YY1-binding protein), a member of the polycomb group (PcG), interacts with MDM2 and decreases MDM2-mediated p53 ubiquitination, leading to stabilization of p53 and an increase in p53 activity. RYBP induces cell-cycle arrest and is involved in the p53 response to DNA damage. Expression of RYBP is decreased in human cancer tissues compared with adjacent normal tissues. These results show that RYBP is a new regulator of the MDM2-p53 loop and that it has tumour suppressor activity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19098711      PMCID: PMC2637313          DOI: 10.1038/embor.2008.231

Source DB:  PubMed          Journal:  EMBO Rep        ISSN: 1469-221X            Impact factor:   8.807


  20 in total

1.  Surfing the p53 network.

Authors:  B Vogelstein; D Lane; A J Levine
Journal:  Nature       Date:  2000-11-16       Impact factor: 49.962

2.  RYBP, a new repressor protein that interacts with components of the mammalian Polycomb complex, and with the transcription factor YY1.

Authors:  E García; C Marcos-Gutiérrez; M del Mar Lorente; J C Moreno; M Vidal
Journal:  EMBO J       Date:  1999-06-15       Impact factor: 11.598

3.  Regulation of p53 stability by Mdm2.

Authors:  M H Kubbutat; S N Jones; K H Vousden
Journal:  Nature       Date:  1997-05-15       Impact factor: 49.962

4.  Mdm2 promotes the rapid degradation of p53.

Authors:  Y Haupt; R Maya; A Kazaz; M Oren
Journal:  Nature       Date:  1997-05-15       Impact factor: 49.962

5.  Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53.

Authors:  S N Jones; A E Roe; L A Donehower; A Bradley
Journal:  Nature       Date:  1995-11-09       Impact factor: 49.962

6.  Ribosomal protein L23 activates p53 by inhibiting MDM2 function in response to ribosomal perturbation but not to translation inhibition.

Authors:  Mu-Shui Dai; Shelya X Zeng; Yetao Jin; Xiao-Xin Sun; Larry David; Hua Lu
Journal:  Mol Cell Biol       Date:  2004-09       Impact factor: 4.272

7.  MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53.

Authors:  Zhuo Zhang; Hui Wang; Mao Li; Sudhir Agrawal; Xinbin Chen; Ruiwen Zhang
Journal:  J Biol Chem       Date:  2004-02-03       Impact factor: 5.157

8.  Human death effector domain-associated factor interacts with the viral apoptosis agonist Apoptin and exerts tumor-preferential cell killing.

Authors:  A A A M Danen-van Oorschot; P Voskamp; M C M J Seelen; M H A M van Miltenburg; M W Bolk; S W Tait; J G R Boesen-de Cock; J L Rohn; J Borst; M H M Noteborn
Journal:  Cell Death Differ       Date:  2004-05       Impact factor: 15.828

9.  Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway.

Authors:  Yanping Zhang; Gabrielle White Wolf; Krishna Bhat; Aiwen Jin; Theresa Allio; William A Burkhart; Yue Xiong
Journal:  Mol Cell Biol       Date:  2003-12       Impact factor: 4.272

10.  Adenoviral-mediated Rybp expression promotes tumor cell-specific apoptosis.

Authors:  R L Novak; A C Phillips
Journal:  Cancer Gene Ther       Date:  2008-06-13       Impact factor: 5.987

View more
  34 in total

1.  Identification of ribosomal protein S25 (RPS25)-MDM2-p53 regulatory feedback loop.

Authors:  X Zhang; W Wang; H Wang; M-H Wang; W Xu; R Zhang
Journal:  Oncogene       Date:  2012-07-09       Impact factor: 9.867

2.  Patient-derived Interstitial Fluids and Predisposition to Aggressive Sporadic Breast Cancer through Collagen Remodeling and Inactivation of p53.

Authors:  Timothy C Kenny; Hank Schmidt; Kerin Adelson; Yujin Hoshida; Anna P Koh; Nagma Shah; John Mandeli; Jess Ting; Doris Germain
Journal:  Clin Cancer Res       Date:  2017-06-19       Impact factor: 12.531

3.  Characterization of non-canonical Polycomb Repressive Complex 1 subunits during early mouse embryogenesis.

Authors:  André Eid; Maria-Elena Torres-Padilla
Journal:  Epigenetics       Date:  2016-04-15       Impact factor: 4.528

Review 4.  Mechanisms of Yin Yang 1 in oncogenesis: the importance of indirect effects.

Authors:  Michael Atchison; Arindam Basu; Kristina Zaprazna; Madhusudhan Papasani
Journal:  Crit Rev Oncog       Date:  2011

Review 5.  The oncogenic role of Yin Yang 1.

Authors:  Qiang Zhang; Daniel B Stovall; Kazushi Inoue; Guangchao Sui
Journal:  Crit Rev Oncog       Date:  2011

6.  Integrative genomic profiling of human prostate cancer.

Authors:  Barry S Taylor; Nikolaus Schultz; Haley Hieronymus; Anuradha Gopalan; Yonghong Xiao; Brett S Carver; Vivek K Arora; Poorvi Kaushik; Ethan Cerami; Boris Reva; Yevgeniy Antipin; Nicholas Mitsiades; Thomas Landers; Igor Dolgalev; John E Major; Manda Wilson; Nicholas D Socci; Alex E Lash; Adriana Heguy; James A Eastham; Howard I Scher; Victor E Reuter; Peter T Scardino; Chris Sander; Charles L Sawyers; William L Gerald
Journal:  Cancer Cell       Date:  2010-06-24       Impact factor: 31.743

Review 7.  Epigenetic dysregulation in hepatocellular carcinoma: focus on polycomb group proteins.

Authors:  Sandy Leung-Kuen Au; Irene Oi-Lin Ng; Chun-Ming Wong
Journal:  Front Med       Date:  2013-04-26       Impact factor: 4.592

8.  miR-9 is an essential oncogenic microRNA specifically overexpressed in mixed lineage leukemia-rearranged leukemia.

Authors:  Ping Chen; Colles Price; Zejuan Li; Yuanyuan Li; Donglin Cao; Anissa Wiley; Chunjiang He; Sandeep Gurbuxani; Rejani B Kunjamma; Hao Huang; Xi Jiang; Stephen Arnovitz; Mengyi Xu; Gia-Ming Hong; Abdel G Elkahloun; Mary Beth Neilly; Mark Wunderlich; Richard A Larson; Michelle M Le Beau; James C Mulloy; Paul P Liu; Janet D Rowley; Jianjun Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-24       Impact factor: 11.205

9.  miR-100 antagonism triggers apoptosis by inhibiting ubiquitination-mediated p53 degradation.

Authors:  G Yang; Y Gong; Q Wang; L Wang; X Zhang
Journal:  Oncogene       Date:  2016-08-15       Impact factor: 9.867

Review 10.  Polycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic Implications.

Authors:  Wei Wang; Jiang-Jiang Qin; Sukesh Voruganti; Subhasree Nag; Jianwei Zhou; Ruiwen Zhang
Journal:  Med Res Rev       Date:  2015-07-30       Impact factor: 12.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.